Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637963 | 1.00 | TTR (0.60) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL8646851 | 0.93 | TTR (0.65) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL3332430 | 0.90 | TTR (0.61) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL5605812 | 0.90 | TTR (0.61) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL5605274 | 0.89 | TTR (0.60) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL12106522 | 0.88 | TTR (0.58) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL8641582 | 0.87 | TTR (0.63) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL8646189 | 0.87 | TTR (0.63) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL13240140 | 0.86 | TTR (0.56) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL6950571 | 0.85 | TTR (0.67) | TTRCYP2C9USP2LMNATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691869-B2 | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs | NICOX S.A. (FR) | 2014-04-08 | — | — | US | disclosed |
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | NICOX SA (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090096314-A1 | ELECTRIC MOTOR | HONDA MOTOR CO., LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | disclosed |
| US-20060122402-A1 | Manufacturing process for no-donating compounds such as no-donating diclofenac | NICOX SA (FR) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | FASN, PTGS1, NOS2 | TTR 1495/4885CYP2C9 123/4885USP2 1533/4885 |
| US-20060122402-A1 | Manufacturing process for no-donating compounds such as no-donating diclofenac | NOS2, NOS1, NOS3 | TTR 2002/4885CYP2C9 10/4885USP2 1318/4885 |
| US-20070010458-A1 | Drugs for the arthritis treatment | PTGS1, ADORA2B, PTGS2 | TTR 693/4885CYP2C9 98/4885USP2 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.